WO2008081927A1 - 抗癌剤の併用による癌治療方法 - Google Patents

抗癌剤の併用による癌治療方法 Download PDF

Info

Publication number
WO2008081927A1
WO2008081927A1 PCT/JP2007/075277 JP2007075277W WO2008081927A1 WO 2008081927 A1 WO2008081927 A1 WO 2008081927A1 JP 2007075277 W JP2007075277 W JP 2007075277W WO 2008081927 A1 WO2008081927 A1 WO 2008081927A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
combination
rituximab
anticancer agents
treating cancer
Prior art date
Application number
PCT/JP2007/075277
Other languages
English (en)
French (fr)
Inventor
Takahito Nakahara
Kentaro Yamanaka
Aya Kita
Hiroshi Koutoku
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to PL07860480T priority Critical patent/PL2127652T3/pl
Priority to ES07860480T priority patent/ES2409755T3/es
Priority to DK07860480.8T priority patent/DK2127652T3/da
Priority to CA002672933A priority patent/CA2672933A1/en
Priority to EP07860480.8A priority patent/EP2127652B1/en
Priority to JP2008552180A priority patent/JP4788774B2/ja
Publication of WO2008081927A1 publication Critical patent/WO2008081927A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　本発明は、医薬、殊に、臭化　1-(2-メトキシエチル)-2-メチル-4,9-ジオキソ-3-(ピラジン-2-イルメチル)-4,9-ジヒドロ-1H-ナフト[2,3-d]イミダゾール-3-イウムを有効成分として含み、カルボプラチン、シスプラチン、パクリタキセル、ビノレルビン、ゲムシタビン、イリノテカン、ドセタキセル、ドキソルビシン、ダカルバジン及びリツキシマブからなる群から選択される１以上の抗癌剤、若しくは、リツキシマブ含有併用療法であるR-ICE及びR-DHAPと併用して適用する治療用組成物に関する。本発明組成物は、全ての固形癌及びリンパ腫、好ましくは、皮膚癌、膀胱癌、乳癌、子宮癌、卵巣癌、前立腺癌、肺癌、大腸癌、膵癌、腎癌、胃癌などの治療に有用である。特に、他の抗癌剤に対して抵抗性の癌に対する治療剤として期待される。
PCT/JP2007/075277 2006-12-29 2007-12-28 抗癌剤の併用による癌治療方法 WO2008081927A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL07860480T PL2127652T3 (pl) 2006-12-29 2007-12-28 Sposób leczenia choroby nowotworowej wykorzystujący czynnik przeciwnowotworowy w kombinacji
ES07860480T ES2409755T3 (es) 2006-12-29 2007-12-28 Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
DK07860480.8T DK2127652T3 (da) 2006-12-29 2007-12-28 Fremgangsmåde til behandling af cancer under anvendelse af anticancermiddel i kombination
CA002672933A CA2672933A1 (en) 2006-12-29 2007-12-28 Method of treating cancer by a combined therapy of anticancer agents
EP07860480.8A EP2127652B1 (en) 2006-12-29 2007-12-28 Method for treating cancer using anticancer agent in combination
JP2008552180A JP4788774B2 (ja) 2006-12-29 2007-12-28 抗癌剤の併用による癌治療方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88280906P 2006-12-29 2006-12-29
US60/882809 2006-12-29
US95077107P 2007-07-19 2007-07-19
US60/950771 2007-07-19

Publications (1)

Publication Number Publication Date
WO2008081927A1 true WO2008081927A1 (ja) 2008-07-10

Family

ID=39588607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/075277 WO2008081927A1 (ja) 2006-12-29 2007-12-28 抗癌剤の併用による癌治療方法

Country Status (9)

Country Link
US (3) US7618992B2 (ja)
EP (2) EP2127652B1 (ja)
JP (2) JP4788774B2 (ja)
CA (1) CA2672933A1 (ja)
DK (1) DK2127652T3 (ja)
ES (1) ES2409755T3 (ja)
PL (1) PL2127652T3 (ja)
PT (1) PT2127652E (ja)
WO (1) WO2008081927A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010146634A1 (ja) * 2009-06-19 2010-12-23 株式会社セレックス 膵臓癌の免疫療法剤及び免疫療法
WO2011029415A1 (en) 2009-09-10 2011-03-17 Univerzita Palackeho Cyclobutan-1,1 -dicarboxylato complexes of platinum with n6-benzyladenine derivatives, method of their preparation and application of these complexes as drugs in antitumour therapy
WO2014142220A1 (ja) * 2013-03-13 2014-09-18 アステラス製薬株式会社 抗腫瘍剤
US11753476B2 (en) 2018-04-08 2023-09-12 Cothera Bioscience, Inc. Combination therapy for cancers with BRAF mutation
US12076399B2 (en) 2017-06-02 2024-09-03 Cothera Bioscience, Inc. Combination therapies for treating cancers

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
GB2471065A (en) * 2009-06-10 2010-12-22 Univ Sheffield Modulator of claspin for treatment of cell proliferative disorder
CA2742342A1 (en) * 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
WO2012167099A1 (en) * 2011-06-01 2012-12-06 Baylor College Of Medicine Biomarkers and therapy for cancer
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
WO2013148649A1 (en) 2012-03-26 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of survivin antagonists in polyomavirus-related disease
US9242000B2 (en) * 2012-10-18 2016-01-26 The Regents Of The University Of California Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
NZ732753A (en) 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
ES2890783T3 (es) 2015-06-22 2022-01-24 Janssen Biotech Inc Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-CD38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
WO2020205739A1 (en) * 2019-03-31 2020-10-08 The Trustees Of The University Of Pennsylvania 'smart' hydrogel for the radiosensitization and sustained delivery of therapeutics triggered by irradiation
WO2020227682A1 (en) * 2019-05-08 2020-11-12 Children's Medical Center Corporation Treating cancer
WO2021155580A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating cancer
WO2023039803A1 (en) * 2021-09-16 2023-03-23 Xiang Li Androgen receptor biomarkers for cancer therapy
WO2023092394A1 (en) * 2021-11-25 2023-06-01 Guo Dagang Methods and compositions for treating ewing family of tumors
WO2023219948A1 (en) * 2022-05-08 2023-11-16 The Regents Of The University Of Colorado, A Body Corporate Therapeutic biomaterial that attenuates the foreign body response

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060803A1 (fr) 2000-02-15 2001-08-23 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazolium fondus
JP2003128548A (ja) 2001-08-10 2003-05-08 Yamanouchi Pharmaceut Co Ltd 縮合イミダゾリウム誘導体を含む医薬組成物
JP2003521913A (ja) 2000-02-02 2003-07-22 アイシス・ファーマシューティカルス・インコーポレーテッド Ｓｕｒｖｉｖｉｎ発現のアンチセンスモジュレーション
WO2004069274A2 (en) 2003-02-07 2004-08-19 Giorgio Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004092160A1 (ja) 2003-04-15 2004-10-28 Astellas Pharma Inc. 臭化物及びその結晶
WO2005042030A1 (en) 2003-10-30 2005-05-12 Aegera Therapeutics, Inc. Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521913A (ja) 2000-02-02 2003-07-22 アイシス・ファーマシューティカルス・インコーポレーテッド Ｓｕｒｖｉｖｉｎ発現のアンチセンスモジュレーション
WO2001060803A1 (fr) 2000-02-15 2001-08-23 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazolium fondus
JP2003128548A (ja) 2001-08-10 2003-05-08 Yamanouchi Pharmaceut Co Ltd 縮合イミダゾリウム誘導体を含む医薬組成物
WO2004069274A2 (en) 2003-02-07 2004-08-19 Giorgio Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004092160A1 (ja) 2003-04-15 2004-10-28 Astellas Pharma Inc. 臭化物及びその結晶
WO2005042030A1 (en) 2003-10-30 2005-05-12 Aegera Therapeutics, Inc. Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
"Journal of Clinical Oncoclogy", ASCO ANNUAL MEETING PROCEEDINGS PART I, vol. 24, no. 18S, 20 June 2006 (2006-06-20)
ANNALS OF ONCOLOGY, vol. 17, no. 3, 2006, pages 23
ANNALS OF ONCOLOGY, vol. 17, no. 4, 2006, pages IV31 - 2
BLOOD., vol. 103, no. 10, 22 January 2004 (2004-01-22), pages 3684 - 8
BLOOD., vol. 107, no. 4, 15 February 2006 (2006-02-15), pages 1555 - 63
CANCER LETT., vol. 232, no. 2, 8 February 2006 (2006-02-08), pages 243 - 54
CANCER, vol. 77, 1996, pages 2458 - 63
CANCER, vol. 89, 2000, pages 1714 - 9
DARIO C. ALTIERI; MD, TRIGGERING: "Cell Death by Targeting TRAIL Receptor and Survivin", CLINICAL SCIENCE SYMPOSIUM SLIDES, 2006
GIODINI A ET AL., CANCER RES, vol. 62, 2002, pages 2462 - 7
INT. J. CANCER, vol. 118, 2006, pages 812 - 20
J CLIN INVEST., vol. 108, no. 7, October 2001 (2001-10-01), pages 981 - 90
KITA A. ET AL.: "Shinki Suvivin Hatsugen Yokuseizai YM155 no Schedule Izonteki na Koshuyo Sayo no Kento", ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, vol. 65TH, 28 August 2006 (2006-08-28), pages 496, XP008142276 *
KITA ET AL., ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, vol. 65, 2006, pages 496
LEUKEMIA & LYMPHOMA, vol. 48, no. 5, May 2007 (2007-05-01), pages 897.904
MESRI M ET AL., AM J PATHOL, 2001, pages 1580757 - 65
MONZO M ET AL., J CLIN ONCOL, vol. 17, 1999, pages 2100 - 4
NAKAGAWA K.: "Haigan no Seibutsugakuteki Joho ni yoru Chiryoho no Rinsho Hyoka", KOSE RODO KAGAKU KENKYUHI HOJOKIN DAI 3 JI TAIGAN SOGO SENRYAKU KENKYU JIGYO ATARASHII YAKUBUTSU RYOHO NO DONYU TO SONO SAITEKIKA NI KANSURU KENKYU, HEISEI 17 NENDO SOKATSU BUNTAN KENKYU HOKOKUSHO, 2006, pages 29 - 30, XP008141148 *
NAKAHARA ET AL., ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, vol. 65, 2006, pages 495 - 6
NAKAHARA T. ET AL.: "Shinki Survivin Hatsugen Yokuseizai YM155 no Hito Hormone Teikosei Zenritsusengan ni Taisuru Koshuyo Sayo", ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION, vol. 65TH, 28 August 2006 (2006-08-28), pages 495 - 496, XP008110576 *
PROC AMER ASSOC CANCER RES, vol. 47, 2006
PROCEEDINGS AACR-NCI-EORTC, 2005
PROSTATE, vol. 65, 2005, pages 10 - 19
SASAKI ET AL., IKAKU NO AYAMI, vol. 164, no. 5, 1993, pages 251 - 254
SASAKI T.: "Biochemical modulation no Kenkyu no Genjo", IGAKU NO AYUMI, vol. 164, no. 5, 30 January 1993 (1993-01-30), pages 251 - 254, XP008109124 *
See also references of EP2127652A4
THE PROSTATE, vol. 64, 2005, pages 293 - 302
TOLCHER A.W. ET AL.: "YM155, A novel survivin suppressant, demonstrates anti-tumor activity in patients with advanced solid tumors and non-Hodgkin's lymphoma", ANNALS OF ONCOLOGY, vol. 17, no. SUPPL. 3, May 2006 (2006-05-01), pages ABSTR. NO. #O.403, XP008109125 *
YAMAMOTO T ET AL., MED ELECTRON MICROSC, vol. 34, 2001, pages 207 - 12
YAMANAKA ET AL., ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, vol. 65, 2006, pages 496
YAMANAKA K. ET AL.: "Shinki Survivin Hatsugen Yokuseizai YM155 no Hito Haigan ni Taisuru Koshuyo Sayo", ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION, vol. 65TH, 28 August 2006 (2006-08-28), pages 496, XP008142273 *
ZHONGHUA WEI CHANG WAI KE ZA ZHI., vol. 8, no. 5, September 2005 (2005-09-01), pages 455 - 8

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010146634A1 (ja) * 2009-06-19 2010-12-23 株式会社セレックス 膵臓癌の免疫療法剤及び免疫療法
JP2011001315A (ja) * 2009-06-19 2011-01-06 Cellex Corp 膵臓癌の免疫療法剤
US8613916B2 (en) 2009-06-19 2013-12-24 Cellex Corporation Immunotherapy for pancreatic cancer
WO2011029415A1 (en) 2009-09-10 2011-03-17 Univerzita Palackeho Cyclobutan-1,1 -dicarboxylato complexes of platinum with n6-benzyladenine derivatives, method of their preparation and application of these complexes as drugs in antitumour therapy
WO2014142220A1 (ja) * 2013-03-13 2014-09-18 アステラス製薬株式会社 抗腫瘍剤
US12076399B2 (en) 2017-06-02 2024-09-03 Cothera Bioscience, Inc. Combination therapies for treating cancers
US11753476B2 (en) 2018-04-08 2023-09-12 Cothera Bioscience, Inc. Combination therapy for cancers with BRAF mutation

Also Published As

Publication number Publication date
USRE45105E1 (en) 2014-09-02
US20080166344A1 (en) 2008-07-10
EP2127652B1 (en) 2013-05-15
US8003105B2 (en) 2011-08-23
EP2609920A1 (en) 2013-07-03
JP2011168619A (ja) 2011-09-01
EP2127652A4 (en) 2010-04-07
JPWO2008081927A1 (ja) 2010-04-30
JP4788774B2 (ja) 2011-10-05
ES2409755T3 (es) 2013-06-27
PL2127652T3 (pl) 2013-10-31
CA2672933A1 (en) 2008-07-10
EP2127652A1 (en) 2009-12-02
US20090263390A1 (en) 2009-10-22
US7618992B2 (en) 2009-11-17
PT2127652E (pt) 2013-07-08
DK2127652T3 (da) 2013-06-10

Similar Documents

Publication Publication Date Title
WO2008081927A1 (ja) 抗癌剤の併用による癌治療方法
JP2007526455A5 (ja)
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
MA32140B1 (fr) Utilisation d&#39;un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens
ECSP055618A (es) Terapia de combinacion para enfermedades hiperproliferativas
WO2005084712A3 (en) Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
EP3040347A3 (en) Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2008094321A3 (en) Akt sensitization of cancer cells
HK1120427A1 (en) Anti-glypican-3 antibody
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2009120697A3 (en) Method and compositions for treatment of cancer
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
WO2008105852A3 (en) Mucoadhesive nanoparticles for cancer treatment
WO2009063970A1 (ja) 抗gpr49抗体を用いる癌の診断および治療
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
RU2010140890A (ru) Улучшенные способы противоопухолевого лечения
WO2006133707A3 (en) Anti-cancer combination treatment and kit-of-part
JP2015514756A5 (ja)
JP2012523435A5 (ja)
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
NZ599878A (en) Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860480

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008552180

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2672933

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007860480

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE